Stock Analysis
Royalty Pharma plc (RPRX) Stock Analysis
Royalty Pharma plc (RPRX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Royalty Pharma plc (RPRX) currently has an AIQ Score of 59/100, indicating a neutral setup. Momentum is the strongest factor at 79/100. Value is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
RPRX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $63.96 |
| AIQ Score | 59/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $27.62B |
| P/E Ratio | 11.87 |
| Forward P/E | — |
| EPS | $0.04 |
| Revenue TTM | $674.14M |
| Dividend Yield | 0.00% |
| Beta | 0.43 |
| Volume | 3.4M |
| 52-week range | $34.08-$64.38 |
| RSI 14 | 73.76 |
| 50-Day SMA | $58.94 |
| 200-Day SMA | $49.23 |
| Analyst Price Target | $62.75 |
| Next Earnings | Nov 4, 2026 |
RPRX
OverviewRPRX Stock Analysis Summary
Royalty Pharma plc (RPRX) currently has an AIQ Score of 59/100, indicating a neutral setup. Momentum is the strongest factor at 79/100. Value is the weakest current factor at 51/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, RPRX has AIQ Score of 59/100 with Momentum base of 79/100 and fading Value at 51/100. Wait for component alignment before adding exposure.
Momentum (79/100) leads while Value (51/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.13% stock move · RPRX classified in Medical - Pharmaceuticals.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is RPRX Bullish or Bearish Right Now?
RPRX currently has a neutral overall setup. Momentum is the strongest factor at 79/100, while Value is weakest at 51/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 79/100.
- - Price is +8.51% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (37 vs 6).
- - Analyst target implies -1.89% downside from the latest quote.
Current Consensus
RPRX's Technical Analysis Consensus is currently Strong Buy, with 37 buy, 2 neutral, and 6 sell votes. RPRX's 14-day RSI is 73.76, which places the stock in an overbought momentum range. RPRX's beta is 0.43, indicating lower market sensitivity than the broad market.
What Changed in RPRX?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the RPRX Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
RPRX Decision Framework
Public evidence layers, setup checks, and risk context for Royalty Pharma plc.
Royalty Pharma plc (RPRX) Stock Analysis
Royalty Pharma plc has an AIQ Score of 59/100 in a Neutral regime. Momentum is strongest at 79/100. Beta is 0.43, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | RPRX is in a Neutral AIQ regime with score 59/100. |
| Signal Conflict | The primary conflict is that momentum leads at 79/100 while value lags at 51/100. |
| Factor Evidence | Momentum 79/100 · Value 51/100 · Quality 53/100 · Risk 53/100 · Sentiment 55/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 79/100.
Momentum is 79/100 and RSI (14) is 73.8.
RPRX is in a Neutral regime at 59/100.
Risk factor is 53/100 with beta 0.43 and annual volatility 22.97%.
Current conflict: momentum leads at 79/100 while value lags at 51/100.
RPRX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
RPRX Fundamentals
RPRX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
RPRX Technical Analysis
RPRX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
RPRX Stock Catalysts
Track RPRX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
RPRX Dividend Analysis
RPRX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
RPRX Financial Data
RPRX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
RPRX Risk Analysis
RPRX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
RPRX Stock News
RPRX stock news, market tone, recent headlines, and catalyst context.
RPRX vs Large Cap Pharma Peers
Current peer cohort: RPRX · TEVA · VRTX · ABBV · AMGN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| RPRX Current stock | 59/100 | 51/100 | 79/100 | 53/100 | 2.35 | 22.97% | Current |
| TEVA Teva Pharmaceutical | 52/100 | 65/100 | 60/100 | 53/100 | 1.8 | 39.91% | RPRX vs TEVA |
| VRTX Vertex Pharmaceuticals | 62/100 | 32/100 | 72/100 | 62/100 | 1.12 | 28.63% | RPRX vs VRTX |
| ABBV AbbVie | 52/100 | 36/100 | 65/100 | 44/100 | 0.69 | 26.62% | RPRX vs ABBV |
| AMGN Amgen | 58/100 | 44/100 | 66/100 | 50/100 | 1.61 | 27.66% | RPRX vs AMGN |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 5, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 6, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching RPRX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for RPRX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
RPRX Stock FAQ
What is RPRX stock price today?
Royalty Pharma plc's current stock price is $63.96. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is RPRX bullish or bearish right now?
RPRX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is RPRX's market cap?
RPRX's market cap is $27.62B based on the latest completed market-close snapshot from Sep 4, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is RPRX's current P/E ratio?
RPRX's current P/E ratio is 11.87 based on the latest completed market-close snapshot from Sep 4, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is RPRX's RSI?
RPRX's 14-day RSI is 73.76 based on the latest completed market-close snapshot from Sep 4, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is RPRX above its 50-day and 200-day moving averages?
RPRX is 8.51% from its 50-day SMA and 29.91% from its 200-day SMA based on the latest completed market-close snapshot from Sep 4, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is RPRX's next earnings date?
RPRX's next earnings date is currently listed as Nov 4, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does RPRX pay a dividend?
RPRX's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 4, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.